Pan American Health Organization
Pan American Health Organization
Measles infections in the United States and Mexico have already exceeded all of 2025, with Pennsylvania recording five deaths and more than 1,000 infections as vaccine exemptions reach an all-time …
With 55,792 confirmed measles cases and 77 deaths across the Americas in 2026, PAHO warns that upcoming religious mass gatherings in South America could accelerate transmission in a region where …
A Pan American Health Organization (PAHO) analysis in The Lancet Regional Health – Americas, published in July 2026, finds 470 million people across 38 countries and territories lived with at …
Mexico’s public mental health system is severely under-resourced even as nearly five million people in Mexico live with a mental health condition. The Instituto Mexicano del Seguro Social (IMSS) fields …
Brazil’s public health system (SUS) has added extended-release lithium on tolerability and adherence grounds, and the Dominican health-insurance regulator, the Superintendency of Health and Occupational Risks (SISALRIL), is studying wider …
A committee of Conitec, Brazil’s health technology assessment body, provisionally recommended ViiV’s HIV-prevention injection at its proposed price of about R$6,660 a year, while Brazil offered Gilead roughly a third …
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
Colombia’s Ministry of Health declared public interest grounds to pursue mandatory licensing of Gilead’s sofosbuvir-based hepatitis C patents, transferring the process to the competition authority for a final determination.
Uruguay’s Ministry of Public Health and mutual insurers have agreed to incorporate 12 high-cost medicines into the national formulary, reducing per-unit acquisition costs from up to 100,000 pesos to approximately …
Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
You must be logged in to post a comment.